Your browser doesn't support javascript.
loading
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
Chamoun, Kamal; Milton, Denái R; Ledesma, Celina; Young, Ken H; Jabbour, Elias J; Alatrash, Gheath; Anderlini, Paolo; Bashir, Qaiser; Ciurea, Stefan O; Marin, David; Molldrem, Jeffrey J; Olson, Amanda L; Oran, Betul; Popat, Uday R; Rondon, Gabriela; Champlin, Richard E; Gulbis, Alison M; Khouri, Issa F.
Afiliación
  • Chamoun K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ledesma C; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Young KH; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alatrash G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Anderlini P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ciurea SO; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Marin D; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Molldrem JJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Olson AL; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Popat UR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rondon G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gulbis AM; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Khouri IF; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ikhouri@mdanderson.org.
Biol Blood Marrow Transplant ; 25(7): 1347-1354, 2019 07.
Article en En | MEDLINE | ID: mdl-30826465
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_lymphomas_multiple_myeloma Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Neoplasias Hematológicas / Trasplante de Células Madre / Bortezomib / Rituximab Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_lymphomas_multiple_myeloma Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Neoplasias Hematológicas / Trasplante de Células Madre / Bortezomib / Rituximab Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article